Mallinckrodt Pharmaceuticals (NYSE:MNK) issued a response today to Sen. Claire McCaskill (D-Mo.) and her probe into the company’s pricing strategies for its injectable pain-killer, Ofirmev.
McCaskill wrote to the company at the end of May, suggesting that that the company’s price increases could have cost hospitals millions and may have pushed healthcare practitioners to use cheaper painkillers, including highly addictive opioids.
Today Mallinckrodt responded to her questions, outlining the context surrounding its price increase for Ofirmev.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt responds to probe into pricey injection pain-killer appeared first on MassDevice.